Alzprotect, a French biopharma company, has successfully completed the open-label extension (OLE) phase of its Phase 2a trial for AZP2006 (ezeprogind®) in treating Progressive Supranuclear Palsy (PSP). Results from the 6-month extension highlight AZP2006’s potential to stabilize or slow disease progression, especially when given in the early stages of PSP.
Key Findings:
- Delay in Disease Progression: In the Phase 2a trial, patients treated with AZP2006 for 3 months showed early signs of delayed disease progression compared to those on placebo.
- Stabilization in Early Disease: During the 6-month open-label extension (OLE), patients who started AZP2006 early in their disease showed significant stabilization of PSP, outperforming those initially on placebo.
- Benefit in Late-Stage PSP: Patients who switched from placebo to AZP2006 in the OLE phase also experienced stabilization, suggesting the treatment may be effective even in advanced stages of PSP.
- Greater Change in Placebo Patients: Patients originally on placebo experienced a greater overall change in disease progression from the beginning of Phase 2a to the end of the OLE compared to those in the active treatment group.
- Safety Profile: No major safety concerns were observed during the OLE, supporting the safety of long-term AZP2006 treatment.
- Precision in Symptom Tracking: The use of PSPRS-10, a precise tool for tracking PSP symptoms, confirmed stabilization in patients who received AZP2006 early.
These findings emphasize the importance of early treatment with AZP2006 in PSP and its potential long-term benefits. The treatment not only stabilized disease progression in early-stage patients but also showed promise in later stages, making it a potential therapeutic option for PSP.
Alzprotect continues to advance AZP2006 in clinical development, aiming to provide new hope for those with PSP.
Dr. Artin Karapet, Chief Medical Officer, highlighted the significance of the results, noting that early and continuous treatment could be key to slowing PSP progression, offering renewed hope for patients.
Phil Verwaerde, CEO, added that the findings strongly support AZP2006’s potential to stabilize PSP, particularly when administered early, with promising results even in advanced stages.
AZP2006 works through a unique mechanism, addressing the root causes of neurodegeneration by stimulating lysosome homeostasis, a critical process for brain function.
